Literature DB >> 15149189

Biotin reagents in antibody pretargeting. 6. Synthesis and in vivo evaluation of astatinated and radioiodinated aryl- and nido-carboranyl-biotin derivatives.

D Scott Wilbur1, Donald K Hamlin, Ming-Kuan Chyan, Brian B Kegley, Janna Quinn, Robert L Vessella.   

Abstract

An investigation has been conducted to prepare and evaluate several radiohalogenated biotin derivatives as part of our studies to develop reagents for carrying (211)At in cancer pretargeting protocols. The primary goal of the investigation was to determine the in vivo stability and distribution properties of astatinated biotin derivatives. In addition to astatination, the biotin derivatives were radioiodinated for in vitro and in vivo comparison. Biodistributions were conducted in athymic mice, with sacrifice times of 1, 4, and 24 h to correspond to 9%, 32%, and 90% of (211)At decay (t(1/2) = 7.21 h). In the investigation, two biotin derivatives, 1a and 2a, were synthesized which had structures that contain a biotin moiety, a biotinidase-blocking moiety, an ether linker moiety, and an aryl stannane moiety for radiohalogenation. Biotin derivatives 1a and 2a were radiolabeled with (125/131)I to give [(125)/(131)I]1b or [(125)I]2b and with (211)At to give [(211)At]1c or [(211)At]2c. In vivo studies demonstrated that co-injected [(125)I]2b and [(131)I]1b had very similar tissue distributions in athymic mice. Co-injection of [(211)At]2c and [(125)I]2b provided data that indicated that rapid deastatination occurred in vivo. A second set of biotin derivatives, 3a, 4a, and 5a, were synthesized which had structures that contain a biotin moiety, a biotinidase-blocking moiety, and an anionic nido-carborane moiety for radiohalogenation. The biotin derivatives 4a and 5a contained an aryl moiety not present in 3a, and 5a had a trialkylamine functionality not present in 3a or 4a. Biotin derivative 3a was radioiodinated, but was not further investigated. Biotin derivatives 4a and 5a were radiolabeled with (211)At and (125)I to produce [(125)I]4b/[(211)At]4c and [(125)I]5b/[(211)At]5c. Comparison of [(125)I]4b and (separately) [(125)I]5b with [(131)I]1b showed that the nido-carborane containing biotin derivatives were retained in blood and tissue more than the aryl iodide derivative. In vivo evaluations of [(211)At]4c/[(125)I]4b and (separately) [(211)At]5c/[(125)I]5b indicated that some deastatination occurred in these compounds, but it was much less than observed for the aryl derivative [(211)At]2c. While the nido-carborane containing biotin derivatives provide a significant improvement in astatine stability over biotin derivatives previously studied, additional derivatives need to be prepared and studied to further improve the in vivo stability and blood/tissue clearance of these compounds.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15149189     DOI: 10.1021/bc034229q

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  9 in total

1.  Halogenated benzimidazole carboxamides target integrin alpha4beta1 on T-cell and B-cell lymphomas.

Authors:  Richard D Carpenter; Arutselvan Natarajan; Edmond Y Lau; Mirela Andrei; Danielle M Solano; Felice C Lightstone; Sally J Denardo; Kit S Lam; Mark J Kurth
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

2.  Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT).

Authors:  Nicoletta Urbano; Stefano Papi; Mauro Ginanneschi; Rita De Santis; Silvia Pace; Ragnar Lindstedt; Liliana Ferrari; Sunju Choi; Giovanni Paganelli; Marco Chinol
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06-06       Impact factor: 9.236

3.  Reagents for astatination of biomolecules. 6. An intact antibody conjugated with a maleimido-closo-decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato-closo-decaborate(2-) reagent via lysine amines.

Authors:  D Scott Wilbur; Ming-Kuan Chyan; Hirohisa Nakamae; Yun Chen; Donald K Hamlin; Erlinda B Santos; Brian T Kornblit; Brenda M Sandmaier
Journal:  Bioconjug Chem       Date:  2012-02-10       Impact factor: 4.774

4.  Preparation and in vivo evaluation of radioiodinated closo-decaborate(2-) derivatives to identify structural components that provide low retention in tissues.

Authors:  D Scott Wilbur; Ming-Kuan Chyan; Donald K Hamlin; Matthew A Perry
Journal:  Nucl Med Biol       Date:  2010-02       Impact factor: 2.408

5.  Astatine Radiopharmaceuticals: Prospects and Problems.

Authors:  Ganesan Vaidyanathan; Michael R Zalutsky
Journal:  Curr Radiopharm       Date:  2008-09-01

6.  Reagents for astatination of biomolecules. 3. Comparison of closo-decaborate(2-) and closo-dodecaborate(2-) moieties as reactive groups for labeling with astatine-211.

Authors:  D Scott Wilbur; Ming-Kuan Chyan; Donald K Hamlin; Matthew A Perry
Journal:  Bioconjug Chem       Date:  2009-03-18       Impact factor: 4.774

Review 7.  Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy.

Authors:  François Guérard; Jean-François Gestin; Martin W Brechbiel
Journal:  Cancer Biother Radiopharm       Date:  2012-10-17       Impact factor: 3.099

8.  Reagents for astatination of biomolecules. 4. Comparison of maleimido-closo-decaborate(2-) and meta-[(211)At]astatobenzoate conjugates for labeling anti-CD45 antibodies with [(211)At]astatine.

Authors:  D Scott Wilbur; Monica S Thakar; Donald K Hamlin; Erlinda B Santos; Ming-Kuan Chyan; Hirohisa Nakamae; John M Pagel; Oliver W Press; Brenda M Sandmaier
Journal:  Bioconjug Chem       Date:  2009-09-04       Impact factor: 4.774

9.  Targeted radionuclide therapy with astatine-211: Oxidative dehalogenation of astatobenzoate conjugates.

Authors:  David Teze; Dumitru-Claudiu Sergentu; Valentina Kalichuk; Jacques Barbet; David Deniaud; Nicolas Galland; Rémi Maurice; Gilles Montavon
Journal:  Sci Rep       Date:  2017-05-31       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.